Filter your results
- 2
- 2
- 2
- 1
- 1
- 2
- 2
- 1
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
sorted by
|
|
CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in AmyloidosisCanadian Journal of Cardiology, 2020, 36 (2), pp.159 - 169. ⟨10.1016/j.cjca.2019.11.036⟩
Journal articles
inserm-03935289v1
|
||
|
CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection FractionCanadian Journal of Cardiology, 2021, 37 (4), pp.531 - 546. ⟨10.1016/j.cjca.2021.01.017⟩
Journal articles
inserm-03934912v1
|